scholarly journals Extracellular Vesicles of Mesenchymal Stem Cells: Therapeutic Properties Discovered with Extraordinary SuccessOK

Biomedicines ◽  
2021 ◽  
Vol 9 (6) ◽  
pp. 667
Author(s):  
Gabriella Racchetti ◽  
Jacopo Meldolesi
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Immune Responses ◽  
Extracellular Vesicles ◽  
Immune Regulation ◽  
Great Increase ◽  
The Body ◽  
Cell Aging ◽  
Therapeutic Effects ◽  
Therapeutic Properties

Mesenchymal stem cells (MSCs), the cells distributed in the stromas of the body, are known for various properties including replication, the potential of various differentiations, the immune-related processes including inflammation. About two decades ago, these cells were shown to play relevant roles in the therapy of numerous diseases, dependent on their immune regulation and their release of cytokines and growth factors, with ensuing activation of favorable enzymes and processes. Such discovery induced great increase of their investigation. Soon thereafter, however, it became clear that therapeutic actions of MSCs are risky, accompanied by serious drawbacks and defects. MSC therapy has been therefore reduced to a few diseases, replaced for the others by their extracellular vesicles, the MSC-EVs. The latter vesicles recapitulate most therapeutic actions of MSCs, with equal or even better efficacies and without the serious drawbacks of the parent cells. In addition, MSC-EVs are characterized by many advantages, among which are their heterogeneities dependent on the stromas of origin, the alleviation of cell aging, the regulation of immune responses and inflammation. Here we illustrate the MSC-EV therapeutic effects, largely mediated by specific miRNAs, covering various diseases and pathological processes occurring in the bones, heart and vessels, kidney, and brain. MSC-EVs operate also on the development of cancers and on COVID-19, where they alleviate the organ lesions induced by the virus. Therapy by MSC-EVs can be improved by combination of their innate potential to engineering processes inducing precise targeting and transfer of drugs. The unique properties of MSC-EVs explain their intense studies, carried out with extraordinary success. Although not yet developed to clinical practice, the perspectives for proximal future are encouraging.

scholarly journals Mesenchymal Stem Cells and Myeloid Derived Suppressor Cells: Common Traits in Immune Regulation

2016 ◽  
Vol 2016 ◽  
pp. 1-17 ◽  
Author(s):  
Irina Lyadova Vladimirovna ◽  
Ekaterina Sosunova ◽  
Alexander Nikolaev ◽  
Tatiana Nenasheva
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Immune Responses ◽  
Immune Regulation ◽  
T Regulatory Cells ◽  
Suppressor Cells ◽  
Myeloid Derived Suppressor Cells ◽  
Regulatory Cells ◽  
B Regulatory Cells ◽  
Immature Cells

To protect host against immune-mediated damage, immune responses are tightly regulated. The regulation of immune responses is mediated by various populations of mature immune cells, such as T regulatory cells and B regulatory cells, but also by immature cells of different origins. In this review, we discuss regulatory properties and mechanisms whereby two distinct populations of immature cells, mesenchymal stem cells, and myeloid derived suppressor cells mediate immune regulation, focusing on their similarities, discrepancies, and potential clinical applications.

scholarly journals Wharton’s Jelly Derived Mesenchymal Stem Cells: Future of Regenerative Medicine? Recent Findings and Clinical Significance

2015 ◽  
Vol 2015 ◽  
pp. 1-11 ◽  
Author(s):  
Ilona Kalaszczynska ◽  
Katarzyna Ferdyn
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Regenerative Medicine ◽  
Adult Stem Cells ◽  
Wharton’S Jelly ◽  
Therapeutic Effects ◽  
Ethical Concerns ◽  
Wharton's Jelly ◽  
Privileged Status ◽  
Therapeutic Properties

Around 5 million annual births in EU and 131 million worldwide give a unique opportunity to collect lifesaving Wharton’s jelly derived mesenchymal stem cells (WJ-MSC). Evidences that these cells possess therapeutic properties are constantly accumulating. Collection of WJ-MSC is done at the time of delivery and it is easy and devoid of side effects associated with collection of adult stem cells from bone marrow or adipose tissue. Likewise, their rate of proliferation, immune privileged status, lack of ethical concerns, nontumorigenic properties make them ideal for both autologous and allogeneic use in regenerative medicine applications. This review provides an outline of the recent findings related to WJ-MSC therapeutic effects and possible advantage they possess over MSC from other sources. Results of first clinical trials conducted to treat immune disorders are highlighted.

scholarly journals Small extracellular vesicles from menstrual blood-derived mesenchymal stem cells (MenSCs) as a novel therapeutic impetus in regenerative medicine

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Lijun Chen ◽  
Jingjing Qu ◽  
Quanhui Mei ◽  
Xin Chen ◽  
Yangxin Fang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Regenerative Medicine ◽  
Extracellular Vesicles ◽  
Clinical Medicine ◽  
Therapeutic Potential ◽  
Menstrual Blood ◽  
Therapeutic Effects ◽  
Basic Characteristics ◽  
Novel Therapeutic

AbstractMenstrual blood-derived mesenchymal stem cells (MenSCs) have great potential in regenerative medicine. MenSC has received increasing attention owing to its impressive therapeutic effects in both preclinical and clinical trials. However, the study of MenSC-derived small extracellular vesicles (EVs) is still in its initial stages, in contrast to some common MSC sources (e.g., bone marrow, umbilical cord, and adipose tissue). We describe the basic characteristics and biological functions of MenSC-derived small EVs. We also demonstrate the therapeutic potential of small EVs in fulminant hepatic failure, myocardial infarction, pulmonary fibrosis, prostate cancer, cutaneous wound, type-1 diabetes mellitus, aged fertility, and potential diseases. Subsequently, novel hotspots with respect to MenSC EV-based therapy are proposed to overcome current challenges. While complexities regarding the therapeutic potential of MenSC EVs continue to be unraveled, advances are rapidly emerging in both basic science and clinical medicine. MenSC EV-based treatment has great potential for treating a series of diseases as a novel therapeutic strategy in regenerative medicine.

scholarly journals Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment

2020 ◽  
Vol 17 (1) ◽  
Author(s):  
Mohsen Keshavarz ◽  
Mir Saeed Ebrahimzadeh ◽  
Seyed Mohammad Miri ◽  
Hassan Dianat-Moghadam ◽  
Seyedeh Sara Ghorbanhosseini ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
T Cell ◽  
Tumor Microenvironment ◽  
Immune Responses ◽  
Newcastle Disease Virus ◽  
Cancer Immunotherapy ◽  
Disease Virus ◽  
Newcastle Disease ◽  
Therapeutic Effects

Abstract Background Human papillomavirus (HPV)-associated malignancy remain a main cause of cancer in men and women. Cancer immunotherapy has represented great potential as a new promising cancer therapeutic approach. Here, we report Mesenchymal stem cells (MSCs) as a carrier for the delivery of oncolytic Newcastle disease virus (NDV) for the treatment of HPV-associated tumor. Methods For this purpose, MSCs obtained from the bone marrow of C57BL mice, then cultured and characterized subsequently by the flow cytometry analysis for the presence of cell surface markers. In this study, we sought out to determine the impacts of MSCs loaded with oncolytic NDV on splenic T cell and cytokine immune responses, caspase-3 and -9 expression, and myeloid and myeloid-derived suppressor cells (MDSCs) by histological and immunohistochemical studies in the tumor microenvironment (TME). Results Our findings proved that MSCs possess both migratory capacity and tumor tropism toward transplanted tumor tissue after peritumoral administration. Tumor therapy experiments indicated that oncolytic NDV delivered by MSCs-engineered system significantly reduces tumor growth, which is associated with the enhancement of E7-specific lymphocyte proliferation, CD8+ T cell cytolysis responses, and splenic IFN-γ, IL-4 and IL-12 responses compared with control groups. Moreover, the treatment upregulated the concentration of apoptotic proteins (caspase 9) and increased infiltration of tumor microenvironment with CD11b + myeloid and Gr1 + MDSCs cells. Conclusions Our data suggest MSCs carrying oncolytic NDV as a potentially effective strategy for cancer immunotherapy through inducing splenic Th1 immune responses and apoptosis in the tumor microenvironment.

scholarly journals Detection of MicroRNAs in Extracellular Vesicles Secreted by Umbilical Cord-derived Mesenchymal Stem Cells

2021 ◽  
Vol 37 (3) ◽  
Author(s):  
Nguyen Thu Huyen ◽  
Duong Minh Chau ◽  
Do Thi Xuan Phuong ◽  
Nguyen Thanh Liem ◽  
Than Thi Trang Uyen
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Umbilical Cord ◽  
Extracellular Vesicles ◽  
Potential Role ◽  
Culture Media ◽  
Therapeutic Effects ◽  
Potential Candidate ◽  
Disease Treatment

Extracellular vesicles (EVs) are emerging as a potential candidate for disease treatment due to their bioactive cargoes. Recently, mesenchymal stem cells (MSC)-derived EVs have shown their capacity to replace parental cells as their similar functions to MSCs. The therapeutic effects of EVs depend on their cargo, such as DNA, miRNA, proteins, and lipids. In this study, we expanded umbilical cord-derived MSCs (UCMSCs) for EV release. Additionally, we evaluated the expression level of several microRNAs in three EV populations, including apoptotic bodies (AB), microvesicles (MV), and exosomes (EX). Results showed that UCMSCs released three EV types: AB, MV, and EX into culture media. The three EV populations were different in morphology and size. Three EVs were detected to carry microRNAs, such as hsa-miR-320, hsa-miR-181b, and hsa-miR-140. Among these microRNAs, hsa-miR-140 expressed with the greatest level, followed by hsa-miR-181b and hsa-miR-320. The results of this study provide more knowledge about UCMSC-derived EV miRNAs in addition to reveal the potential role of UCMSC-EVs associated with detected miRNAs.

scholarly journals Application of Mesenchymal Stem Cells in Inflammatory and Fibrotic Diseases

2020 ◽  
Vol 21 (21) ◽  
pp. 8366
Author(s):  
Jae-Sung Ryu ◽  
Eun-Jeong Jeong ◽  
Jong-Yeup Kim ◽  
Soon Ju Park ◽  
Won Seok Ju ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Trophic Factors ◽  
Therapeutic Effects ◽  
Multipotent Stem Cells ◽  
Therapeutic Properties ◽  
Fibrotic Diseases ◽  
Plastic Surfaces

Mesenchymal stem cells (MSCs) are multipotent stem cells that can be isolated from various tissues in the adult body. MSCs should be characterized by three criteria for regenerative medicine. MSCs must (1) adhere to plastic surfaces, (2) express specific surface antigens, and (3) differentiate into mesodermal lineages, including chondrocytes, osteoblasts, and adipocytes, in vitro. Interestingly, MSCs have immunomodulatory features and secrete trophic factors and immune receptors that regulate the microenvironment in host tissue. These specific and unique therapeutic properties make MSCs ideal as therapeutic agents in vivo. Specifically, pre-clinical and clinical investigators generated inflammatory and fibrotic diseases models, and then transplantation of MSCs into diseases models for therapeutic effects investigation. In this review, we characterize MSCs from various tissues and describe their applications for treating various inflammation and fibrotic diseases.

scholarly journals Mesenchymal stem cells and extracellular vesicles in therapy against kidney diseases

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yuling Huang ◽  
Lina Yang
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Extracellular Vesicles ◽  
Kidney Diseases ◽  
Kidney Injury ◽  
Trophic Factors ◽  
Therapeutic Effects ◽  
Future Clinical Practice ◽  
Important Means ◽  
Preclinical And Clinical Studies

AbstractKidney diseases pose a threat to human health due to their rising incidence and fatality rate. In preclinical and clinical studies, it has been acknowledged that mesenchymal stem cells (MSCs) are effective and safe when used to treat kidney diseases. MSCs play their role mainly by secreting trophic factors and delivering extracellular vesicles (EVs). The genetic materials and proteins contained in the MSC-derived EVs (MSC-EVs), as an important means of cellular communication, have become a research focus for targeted therapy of kidney diseases. At present, MSC-EVs have shown evident therapeutic effects on acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy (DN), and atherosclerotic renovascular disease (ARVD); however, their roles in the transplanted kidney remain controversial. This review summarises the mechanisms by which MSC-EVs treat these diseases in animal models and proposes certain problems, expecting to facilitate corresponding future clinical practice.

Sign in / Sign up

Export Citation Format

Share Document